Couverture de ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

De : American College of Cardiology
Écouter gratuitement

À propos de ce contenu audio

The American College of Cardiology offers select interviews and summaries of cardiology's most interesting research areas from ACCEL's renowned library, hosted by ACCEL Editor-in-Chief Alison L. Bailey, MD, FACC, FAACPVR.American College of Cardiology Foundation. All rights reserved. Hygiène et vie saine Maladie et pathologies physiques
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !
    Épisodes
    • NOTIFY-PICTURE Trial: Real-Time Notification of AI-Derived Incidental CAC on Statin Initiation
      Feb 17 2026

      What exactly is incidental coronary artery calcification, and what does it mean when artificial intelligence identifies these calcifications? Incidental coronary artery calcification refers to calcium deposits in the coronary arteries that are detected on imaging studies performed for unrelated reasons. AI now enables clinicians to repurpose routine clinical images to efficiently and scalably assess an individual's risk of atherosclerotic coronary disease. How best to translate these AI‑driven insights into meaningful changes in patient care, however, remains an important area for continued research and clinical guidance.

      In this interview, C. Noel Bairey Merz MD, MACC and Ramzi Dudum MD, FACC discuss the NOTIFY-PICTURE Trial: Effects of Real-Time Notification of AI-Detected Incidental Coronary Artery Calcium on Statin Prescription.

      Afficher plus Afficher moins
      10 min
    • VESALIUS-CV Trial: Effect of Evolocumab in Patients at CV Risk without Prior MI or Stroke
      Feb 10 2026

      The VESALIUS‑CV trial demonstrated that adding the PCSK9 inhibitor evolocumab to optimized lipid‑lowering therapy significantly reduced the risk of first major cardiovascular events by 25% in high‑risk adults without prior heart attack or stroke and cut the risk of first heart attack by 36%. These results confirm that intensive LDL‑C lowering with evolocumab provides meaningful primary‑prevention benefits in patients with atherosclerosis or diabetes, achieving substantial event reduction over more than four years of follow‑up.

      In this interview, Nanette Kass Wenger MD, MACC and Erin A. Bohula, MD, FACC discuss the VESALIUS-CV Trial: Effect of Evolocumab in Patients at CV Risk without Prior MI or Stroke.

      Afficher plus Afficher moins
      9 min
    • ACCEL Lite: Hypertension Treatment Trials in the Elderly for Brain Health
      Feb 3 2026

      Is the evidence convincing that intensive antihypertensive therapy protects brain function and helps prevent dementia? Research increasingly shows that high mid‑life blood pressure is a strong predictor of later cognitive decline. Emerging data further indicate that intensive blood‑pressure lowering can reduce the risk of cognitive impairment and dementia while remaining safe for many older adults.

      In this interview, Glenn A. Hirsch MD, MHS, FACC and Paul K Whelton, MB, MD, MSc discuss "Hypertension Treatment Trials in the Elderly for Brain Health".

      Afficher plus Afficher moins
      13 min
    Aucun commentaire pour le moment